Holobiome
Biotechnology company developing microbiome-based therapeutics targeting the gut-brain axis for neurological and psychiatric disorders.
Notes
Holobiome is a biotechnology company pioneering the development of microbiome-based therapeutics that target the gut-brain axis. The company's research focuses on understanding how gut bacteria communicate with the nervous system and developing therapies that can modulate this communication for treating neurological and psychiatric disorders.
The gut-brain axis represents a bidirectional communication network between the gastrointestinal tract and the central nervous system. Growing evidence suggests that gut microbiota play important roles in brain development, behavior, and neurological disease.
Holobiome is backed by Corundum Systems Biology and other investors focused on novel approaches to drug development.
Team
- Phil Strandwitz, Ph.D. - CEO & Co-founder
- LinkedIn: linkedin.com/in/philstrandwitz
- Team with expertise in microbiology and neuroscience
Additional Research Findings
- Founded in 2015, based in Cambridge, MA
- Portfolio company of Corundum Systems Biology
- Gut-brain axis therapeutic focus
- Microbiome-based drug discovery platform
- Targeting neurological and psychiatric conditions
- Novel approach to CNS drug development
- Leverages gut microbiome research advances
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Corundum Systems Biology | Tokyo, Japan | biotech-focused | seedseries-a+1 | 9 |